A first-of-its-kind study is just getting underway at University of Minnesota Physicians Heart at Fairview, in Minneapolis. The FDA-approved trial is designed to test the impact of stem cells on restoring the heart’s muscle function in patients suffering from advanced heart failure. The results of the trial could impact the future of health care in the area of heart disease, and may one day save lives (…)
“This trial is designed for heart failure patients in the end stage of heart failure, with no options for treatment,” explained Ganesh Raveendran, M.D., who is the principal investigator of the clinical trial.
New research has found that stem cells derived from human cord blood could be an effective alternative in repairing heart attacks.
At least 20 million people survive heart attacks and strokes every year, according to World Health Organisation estimates, but many have poor life expectancy and require continual costly clinical care. The use of patient’s own stem cells may repair heart attacks, although their benefit may be limited due to scarce availability and ageing. The researchers have found heart muscle-like cells grown using stem cells from human umbilical cord blood could help repair heart muscle cells damaged by a heart
It has long been thought that damage to the heart is irreversible, but new research is challenging that assumption.
Investigators from Children’s Hospital Boston were able to reverse heart damage in mice by stimulating the growth of new heart muscle cells.
They did this by injecting the mice with the growth factor neuregulin1, which is a key player in heart cell growth.
Until recently, most experts believed that the heart muscle could not repair itself, in part because the cells responsible for its development stop proliferating after birth.
But recent studies have shown that these heart muscle cells, known as cardiomyocytes, do have
Adipose Stem Cell Heart Attack Trial Data Published in Journal of the American College of Cardiology; Cytori’s APOLLO Trial Demonstrated Safety & Feasibility and Improvements in Cardiac Function
Cytori Therapeutics announced today the publication of previously reported six-month outcomes from APOLLO, the Company’s European clinical trial evaluating adipose-derived stem and regenerative cells (ADRCs) in patients with acute myocardial infarction (heart attack or AMI), as Research Correspondence in the Journal of the American College of Cardiology. The APOLLO trial was a 14-patient, prospective, randomized, double-blind, placebo-controlled, feasibility trial (Phase I/IIA) evaluating autologous ADRCs extracted with the Company’s proprietary Celution® System for
A 41-site clinical trial, testing the restorative effect that adult bone marrow stem cells have on damaged or injured myocardium in heart attack patients, is being led at Wake Forest Baptist by Sanjay Gandhi, MD.
Phase I of the research study found that stem cells derived from bone marrow (mesenchymal stem cells) were safe for patients and may have the ability to limit scar formation, improve heart function and preserve tissue following a first heart attack.
Phase I was a multicenter study of 53 patients which demonstrated that the treatment was safe in adults, and those patients given this